Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer Index (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.
For more information, visit: http://www.breastcancerindex.com
http://www.answersbeyond5.com
http://www.twitter.com/answersbyond5
Advertisement